Search This Blog

Monday, July 20, 2020

U.S. firms fear workplace coronavirus precautions do not address airborne risk

U.S. companies are raising new questions about how they can make workplaces safe after the world’s top public health agency acknowledged the risk that tiny airborne droplets of the novel coronavirus may contribute to its spread, industry healthcare consultants said.

About two weeks ago, the World Health Organization called for more scientific study into airborne transmission of COVID-19. The move raised awareness of an issue excluded from U.S. government back-to-work guidelines, adding to the challenge of keeping people safe in offices, stores and work sites, these consultants said.
Many companies devised strategies based on WHO guidance that large respiratory droplets of the virus could infect people when first emitted and after they landed on surfaces. Now the concern over infection is focused on the idea that tiny droplets could linger in the air for hours.
Companies are reviewing if they have gone far enough with policies on mask-wearing, sealing off conference rooms and upgrading ventilation systems. Some, like retailers who have installed plexiglass barriers in their stores between cashiers and customers, are wondering what else they can do if the larger droplets those barriers aim to contain are just one piece of respiratory transmission, consultants said.
Neal Mills, chief medical officer at healthcare benefits group Aon, began fielding questions last week about the WHO’s decision to investigate aerosol transmission, and said employers were slowing the return of remote workers back to their offices.
“They are doing due diligence around how are you going to reduce the transmission of the virus in light of the proposed aerosol nature of COVID-19,” Mills said.
The slowdown comes as some employers, such as Texas energy companies Halliburton Co and Chevron Corp, had already begun delaying plans to bring back office workers due to rising coronavirus cases.
Employers are asking whether public health recommendations that individuals remain 6 feet apart and wear masks to limit transmission through large droplets are enough.
They also wonder about air conditioning systems that do not have filtration systems and the effectiveness of plexiglass partitions against a virus floating in the air, said David Zieg, a lead consultant on clinical services at Mercer, another healthcare services companies.
Consultants are advising employers to go beyond their existing plans, which may also include temperature checks, health questionnaires and frequent restroom cleanings.
“The concept here is risk reduction. It’s not 100%. You add in all the little things you can to reduce the risk,” Zieg said.
Months after U.S. companies sent all but essential workers home due to the global new coronavirus pandemic, many are still struggling to bring their workforce back.
For some employers, the cost of not putting in effective precautions goes beyond that of workers missing days while they are sick. There are concerns about legal liability and healthcare costs, many of which are paid for by large employers.
Some corporations moved early and began integrating the possibility of airborne transmission of COVID-19 into their plans as evidence began emerging of transmission at indoor bars and restaurants.
General Motors Co, Ford Motor Co and Fiat Chrysler Automobiles NV maximized ventilation in their manufacturing facilities before restarting production on May 18 because of the potential for aerosol transmission, the companies said.
But others are more than halving the number of workers they bring back to the office to 10 percent of staff and rethinking how many people can safely ride in an elevator or attend an in-person meeting, Willis Towers Watson health practice co-leader Jeff Levin-Scherz said.
“Once you start limiting how many people can be in a conference room, the imperative to bring some types of workers back to the office, if they have to attend meetings virtually anyway, is much lower,” Towers Watson’s Levin-Scherz said.

FDA sets action date for Osmotica’s Arbaclofen in MS

The FDA has set a December 29 action date for its review of Osmotica Pharmaceutics’ (OSMT +1.2%refiled marketing application seeking approval of arbaclofen extended-release tablets for the treatment of spasticity in multiple sclerosis patients.
The amended submission includes data from two studies, a Phase 3 and its long-term open-label extension.

United to improve airflow, filtration, board, deplane fewer passengers at once

United Airlines Holdings Inc. UAL, -3.66% announced ways it was looking to make air travel safer for passengers, through improving air flow and filtration and limiting the number of passengers that can board and deplane at a time. The air carrier said it will now maximize air flow volume for all high-efficiency particular rate (HEPA) filtration systems during the boarding and deplaning process. The company said the air conditioning systems on its aircraft recirculates the air every 2 to 3 minutes and removes 99.97% of particles, including viruses and bacteria. United said it was also taking steps to limit the number of passengers on its planes, saying only 15% of its flights had more than 70% of the seats filled. In addition, the company said it would board fewer customers at a time and will deplane in groups of five rows at a time. The stock, which fell 3.5% in morning trading, has tumbled 62.8% year to date, while the U.S. Global Jets ETF JETS, -2.19% has dropped 48.8% and the S&P 500 SPX, 0.41% has gained 0.1%.

Trump says he’s restarting coronavirus briefings beginning Tuesday

President Donald Trump said Monday he will resume giving daily briefings on his administration’s response to the coronavirus. Speaking in the Oval Office, he told reporters the next one will be Tuesday afternoon at 5 p.m. Eastern. Trump regularly joined such briefings in March and April, but hasn’t joined one since late April. White House counselor Kellyanne Conway has advocated for Trump to resume giving regular coronavirus briefings.

IBio soars, Novavax, Inovio fall amid news on other Covid vaccine candidates

Shares of companies with COVID-19 vaccine candidates were mixed in volatile trading Monday, after the promising results from trials of vaccine candidates from Pfizer Inc. PFE, 0.83% and BioNTech SE BNTX, 4.28% and AstraZeneca PLC AZN, -2.55% AZN, 1.95%. Shares of iBio Inc. IBIO, 72.38%, which is working with Beijing CC-Pharming Ltd. on a plant-based vaccine to treat the coronavirus, soared 43% in morning trading on volume of 45.5 million shares, which is already nearly double the full-day average. Inovio Pharmaceuticals Inc. INO, -6.86%, which announced last month that the Department of Defense will pay $71 million to fund the manufacturing of a device used to administer Inovio vaccines, saw its stock drop 7.9%. Among other companies with vaccine candidates, shares of Moderna Inc. MRNA, -10.48% sank 12% in active trading after a J.P. Morgan downgrade on valuation concerns, Novavax Inc. NVAX, -4.28% shed 5%, Vaxart Inc. VXRT, -0.83% gained 1.9%. Meanwhile, shares of AstraZeneca fell 2.9%, Pfizer gained 1.8% and BioNTech advanced 4.9%. The S&P 500 SPX, 0.32% was up less than 0.1% in morning trading.

AstraZeneca falls as early-stage data on coronavirus vaccine are published

Shares of AstraZeneca AZN, -2.56% AZN, 2.18% were down 3.4% in trading on Monday after a medical journal published a study that found the company’s COVID-19 vaccine candidate produced antibody and T-cell responses in participants in a Phase 1/2 clinical trial. AstraZeneca is developing the experimental vaccine with the University of Oxford; the study was published in The Lancet. The single-blind, randomized, controlled trial found that neutralizing antibody responses were reported in 91% of 35 patients when utilizing one test and 100% of 35 patients when using a different test. It also found that T-cell responses peaked on day 14. “A single dose elicited both humoral and cellular responses against SARS-CoV-2, with a booster immunization augmenting neutralizing antibody titers,” the study’s authors wrote. BioNTech BNTX, 4.30% and Pfizer Inc. PFE, 1.34%, which are also developing a COVID-19 vaccine, said earlier on Monday that their vaccine candidate produced a T-cell response in participants in an early-stage trial in Germany. AstraZeneca’s stock has gained 21.3% year-to-date, in comparison with the S&P 500 SPX, 0.24%, which is down 0.2%.

FDA guides on development plans for Immuron’s new oral therapeutic

Immuron (NASDAQ:IMRN) surges 89% premarket after the Naval Medical Research Center (NMRC) received written FDA guidance in relation to the clinical development pathway of the company’s new investigational drug being developed for the treatment of moderate to severe campylobacteriosis and Enterotoxigenic Escherichia coli infections.
The Type B meeting with the FDA discussed the Chemistry, Manufacturing and Controls, including the proposed release testing specifications of the product as well as the planned clinical studies evaluating the safety and efficacy.
The company expects to conduct two human phase II clinical trials in 2021.
On June 19, Immuron provided an update on the collaboration with NMRC.